{"id":1434,"date":"2026-01-08T17:55:32","date_gmt":"2026-01-08T17:55:32","guid":{"rendered":"https:\/\/www.doctaforum-events.org\/2026\/cursocp2026\/?page_id=1434"},"modified":"2026-03-26T10:26:15","modified_gmt":"2026-03-26T10:26:15","slug":"bibliografia","status":"publish","type":"page","link":"https:\/\/www.doctaforum-events.org\/2026\/cursocp2026\/bibliografia\/","title":{"rendered":"Presentaciones \/ Bibliograf\u00eda"},"content":{"rendered":"

PRESENTACIONES<\/span><\/p>\n

 <\/p>\n

 <\/p>\n\n\n\n\n\n\n\n\n
SESI\u00d3N I<\/td>\n<\/tr>\n
1. Epidemiolog\u00eda<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
2. Cribado<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
3. Diagn\u00f3stico cl\u00ednico y estadificaci\u00f3n<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
4. Diagn\u00f3stico anatomo-patol\u00f3gico y molecular (NGS, biopsia l\u00edquida)<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
5. Abordaje multidisciplinar del c\u00e1ncer de pulm\u00f3n: comit\u00e9s de tumores tor\u00e1cicos y molecular tumor board<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n
SESI\u00d3N II<\/td>\n<\/tr>\n
6. La importancia de los tratamientos locales en estadios iniciales (cirug\u00eda, SRBT)<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
7. Tratamiento neoadyuvante, perioperatorio y adyuvante<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
8. Tratamiento de la enfermedad localmente avanzada irresecable<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n
SESI\u00d3N III<\/td>\n<\/tr>\n
9. Primera l\u00ednea de tratamiento en CPNM avanzado<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
10. Segunda l\u00ednea de tratamiento y sucesivas en CPNM avanzado<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
11. Tratamiento de la enfermedad oligometast\u00e1sica y met\u00e1stasis cerebrales<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
12. Manejo de toxicidades inmuno relacionadas (IO, ADCs)<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n\n
SESI\u00d3N IV<\/td>\n<\/tr>\n
13. Primera l\u00ednea de tratamiento en mutaci\u00f3n EGFR<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
14. Reordenamientos de ALK y ROS1<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
15. Mutaciones de KRAS<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
16. Otras alteraciones moleculares: BRAF, NTRK, RET, MET<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
17. Mecanismos de resistencia y tratamientos posteriores en enfermedad con driver<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n
SESI\u00d3N V<\/td>\n<\/tr>\n
18. C\u00e1ncer de pulm\u00f3n microc\u00edtico<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
19. Tumores t\u00edmicos<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
20. Tumores neuroendocrinos<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
21. Mesotelioma pleural<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

 <\/p>\n

BIBLIOGRAF\u00cdA<\/span><\/p>\n

 <\/p>\n

 
\n\n\n\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
SESI\u00d3N I<\/td>\n<\/tr>\n
Cancer statistics 2026 Ca Cancer J Clin Siegel 2026<\/span>
\n<\/td>		\"\"<\/a><\/td>\n<\/tr>\n
Estimaciones de la incidencia del c\u00e1ncer en Espa\u00f1a 2026 REDECAN<\/span>
\n<\/td>		\"\"<\/a>
\n<\/td>\n<\/tr>\n
European cancer mortality predictions for the year 2026 Ann Oncol Santucci 2026<\/span>
\n<\/td>		\"\"<\/a>
\n<\/td>\n<\/tr>\n
GCO Fact sheets Lung GLOBOCAN 2022<\/span>
\n<\/td>		\"\"<\/a>
\n<\/td>\n<\/tr>\n
Global burden of lung cancer 2022 and projections to 2050 Cancer Epidemiol Zhou 2024<\/span>
\n<\/td>		\"\"<\/a>
\n<\/td>\n<\/tr>\n
Lung adenocarcinoma promotion by air pollutants Nature Hill 2023<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Lung cancer in never smokers Trends in Cancer Caswell 2026<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Lung cancer in nonsmoking individuals JAMA Murphy 2025<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Radon and lung cancer CROH Liu 2024<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Second primary lung cancer in lung cancer survivors JTO Jensen 2024<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/p>\n\n\n\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
SESI\u00d3N II<\/td>\n<\/tr>\n
Cascone, Tina et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Chaft, Jamie E et al. Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Ce<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Dunne, Elizabeth G et al. The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lun<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
eymach, John V et al. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Felip, E et al. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-II<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Forde PM, et al. N Engl J Med. 2018 Apr 16. doi- 10.1056-NEJMoa1716078<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Garassino, Marina C et al. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresecta<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Girard, Nicolas et al. Treatment Characteristics and Real-World Progression-Free Survival in Patien<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Han, Yuelin et al. Efficacy and safety of perioperative immunotherapy combinations for resectabl<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Herbst, Roy S et al. COAST An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alo<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Immunotherapy for resectable lung cancer. Forde, P_CNCR-131-e35849<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Jabbour, Salma K et al. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Lee, Jay M et al. Phase 3 Trials of Neoadjuvant, Perioperative, and Adjuvant Chemoimmunotherap<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Lu, S et al. Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal gro<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Lu, Shun et al. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Lu, Shun et al. Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-S<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Meta-Analysis of Concomitant Versus Sequential_Auperin2010<\/span><\/td>\"\"<\/a>
\n<\/td>\n<\/tr>\n
Nat Med. 2024 Jan;30(1)218-228<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. Forde, P_CM816OS<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC S.J. Antonia, A<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Paz-Ares, L et al. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage I<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Perioperative Nivolumab_Checkmate77T_Cascone T<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Peters, Solange et al. Progression-Free and Overall Survival for Concurrent Nivolumab<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Provencio et al. NEJM_NADIM II . 2023<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Provencio et al. Perioperative chemotherapy and nivolumab in NSCLC (NADIM) 5year clinical out<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Socinski, Mark A et al. Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
Spigel, David R et al. Five-Year Survival Outcomes From the PACIFIC Trial Durvalumab After Chem<\/span><\/td>\"\"<\/a>
\n<\/td>\n<\/tr>\n
Surgery NADIM I EJCTS 2021<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
2025 Inmnuno corela OR y PFS con SG<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
2025 ASCO no driver<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
2025 biespecificos inmuno<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
2025 inmuno nuevas generaciones<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
2025 relacion respuesta inmuno con caracterist<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
2025 resistenci a inmu<\/span><\/td>\"\"<\/a><\/td>\n<\/tr>\n
2025. PD-L1 negati<\/span><\/td>\"\"<\/a>
\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
SESI\u00d3N III<\/td>\n<\/tr>\n
Ashworth Metanalisis Prx factors oligoM1 Clin Lung Cancer 2014<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Dingermans Def Synchronous OligoM1 NSCLC JTO 2019<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Golberg Ph2 brain M1 pembro Lancet Oncol 2020<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Goldberg S et al. Lancet Oncol 2016<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Gomez Ph 2 OS_J. Clin. Oncol. 2019<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Gomez Ph2 LAT vs maintenance OligoM1 Lancet Oncol. 2016<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Guckenberger Characterisation and classification of oligometastatic disease_consensus def OlidM<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
GuckenbergerMultimodality treatment oligoM1 NSCLC ETOP CHESS trial Lung cancer 2024<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Hendriks OligoM1 NSCLC def Eur J Cancer 2019<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
insights-oligometastatic-non-small-cell-lung-cancer-2025<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
jamaoncology_bauml_2019_oi_190036<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
jamaoncology_iyengar_2017_oi_170069<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
jamaoncology_theelen_2019_oi_190039<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Jongblows Pronostic predictive oligoM1 NSCLC JTO 2024<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Kilickap Brain M1 cemiplimab PDL1h Cancer 2025<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Levy EORTC conscnesus Synchronous oligoM1 disease Eur J Cancer 2019<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Li durva with CT ans SABRT NSCLC Ph2 Int J Rad oncol 2025<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Mansfield et al. pooled analysis brain m1 JTO CRR 2021<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Nadal Atezobrain Ph2 JCO 2023<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
NSCLC 1L. Nuevas Inmunoterapias. Revisi\u00f3n. Li 2024<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
NSCLC 2L. Resistencia a IT. Net Rev. Reck 2025<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
NSCLC. Resistencias a IT. Wong. 2025<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Paz-Ares et al. J Thorac Oncol 2023<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Powell et al. Pmebro chemo Brain M1 poo\u00f1led analysis J Thorac Oncol 2021<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Reck et al. J Thorac Oncol 2023<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Rhun EANO ESMO BrainM1 guidelines Ann Oncol 2021<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Sampat rev brainM1 frontiers 2024<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Vilari\u00f1o Immunotherapy in brain M1 Cancer treatment rev 2020<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
vogelbaum-et-al-2021-treatment-for-brain-metastases-asco-sno-astro-guideline<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Zhao Intracraneal response tisle MBrain M1 Transl Lunc Cancer Res 2024<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
SESI\u00d3N IV<\/td>\n<\/tr>\n
1STLINE EGFR<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
2025 . RET 2<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
2025 ASCO driver<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
2025 met<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
2025 RET<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
2025 target terapies<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
2025. NTRK<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
EGFR – Resistencias revision. 2025<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Emerging landscape of KRAS inhibitors in cancer tretament Cancer Cell Riedl 2026<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Exploiting therapeutic implications of KRAS inh on tumor immunity Cancer Cell Molina-Arcas 2024<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
KRAS Targeted therapies in cancer BMJ Tang 2025<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
MARIPOSA, FLAURA2, FLAURA<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Mec Resistencia Terapias dirigidas. 1. 3001198_258<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Mec Resistencia Terapias dirigidas. 2<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Ou, Med Com 2024. resistencias a T Dirigidas<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
SESI\u00d3N V<\/td>\n<\/tr>\n
ADRIATIC manuscript_NEJM September 2024<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Capdevila SEOM GETNE NETs 2023<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
CMP Revi C\u00e1ncer24 D\u00d3MINE<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
EPD and CT vs CT alone for MPM Ph 3 MARS 2 trial Lancet Resp Med Lancet Resp Med Lim 2024<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Heijboer Treatment outcomes LCNEC Lung cancer 2025<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
IDeate-Lung01<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Immunotherapy approaches for MPM Nat Rev Clin Oncol Fennell 2022<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Lung and timic carcinoid tumors guidelines_AnnOncol2021<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Lung Neuroendocrine Tumors classification_Hystopathology2024<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Lurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Moving beyond morphology. Morpho-molecular classification of MPM JTO Drevet 2026<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Nassar molecular charact LCNELCNature 2025<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Nivolumab-Ipliimumab in MPM CM 742 JCO Scherpereel 2026<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Nordic guidelines lung NET_2023<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Pembrolizumab plus CT vs CT in MPM Ph 3 IND227 Lancet Chu 2023<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Radiant 4 trial Lancet 2016<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Schmith DLL3 Expression in Neuroendocrine Carcinomas Endocr Path 2025<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Sen pulmonary neuroendocrine neoplasm Lancet Oncol 2025<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
TARLATAMAB.2ND LINEpdf<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
Wermke Ph1 Obrixtamig SCLC and LNEC JCO 2025<\/span><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

PRESENTACIONES     SESI\u00d3N I 1. Epidemiolog\u00eda 2. Cribado 3. Diagn\u00f3stico cl\u00ednico y estadificaci\u00f3n 4. Diagn\u00f3stico anatomo-patol\u00f3gico y molecular (NGS, biopsia l\u00edquida) 5. Abordaje multidisciplinar del c\u00e1ncer de pulm\u00f3n: comit\u00e9s de tumores tor\u00e1cicos y molecular tumor board SESI\u00d3N II 6. La importancia de los tratamientos locales en estadios iniciales (cirug\u00eda, SRBT) 7. Tratamiento neoadyuvante, perioperatorio […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1434","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.doctaforum-events.org\/2026\/cursocp2026\/wp-json\/wp\/v2\/pages\/1434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.doctaforum-events.org\/2026\/cursocp2026\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.doctaforum-events.org\/2026\/cursocp2026\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.doctaforum-events.org\/2026\/cursocp2026\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.doctaforum-events.org\/2026\/cursocp2026\/wp-json\/wp\/v2\/comments?post=1434"}],"version-history":[{"count":2,"href":"https:\/\/www.doctaforum-events.org\/2026\/cursocp2026\/wp-json\/wp\/v2\/pages\/1434\/revisions"}],"predecessor-version":[{"id":1436,"href":"https:\/\/www.doctaforum-events.org\/2026\/cursocp2026\/wp-json\/wp\/v2\/pages\/1434\/revisions\/1436"}],"wp:attachment":[{"href":"https:\/\/www.doctaforum-events.org\/2026\/cursocp2026\/wp-json\/wp\/v2\/media?parent=1434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}